J&J Launches Shockwave C2 Aero IVL Catheter Globally, Banks on Tremfya and Icotyde
Tremfya and newly approved Icotyde will spearhead Johnson & Johnson’s immunology growth as Stelara contends with biosimilar entrants. The company has rolled out its Shockwave C2 Aero Coronary IVL Catheter globally to enhance calcium modification in interventional cardiology and diversify device revenues.
1. Immunology Strategy
Johnson & Johnson is prioritizing Tremfya, its psoriasis blockbuster, and Icotyde, recently approved for inflammatory bowel disease, to drive immunology sales as its flagship drug Stelara faces biosimilar launches in Europe and Asia. The company expects combined annual immunology revenue from these therapies to offset declining Stelara volumes and strengthen its autoimmune portfolio.
2. Coronary IVL Catheter Launch
J&J has initiated a global commercial rollout of the Shockwave C2 Aero Coronary Intravascular Lithotripsy (IVL) Catheter, designed to treat calcified coronary lesions with sonic pressure waves. The low-profile device expands the company’s interventional cardiology offerings and aims to capture share in the rapidly growing calcium-modification market segment.